摘要
目的探讨莫西沙星联合头孢哌酮钠舒巴坦钠治疗老年重症肺炎的疗效。方法选择80例老年重症肺炎患者,随机分为两组,对照组每12 h静脉滴注头孢哌酮钠舒巴坦钠3.0 g;观察组在此基础上,每天再静脉滴注莫西沙星0.4 g,疗程为7~14 d。结果观察组总有效率为87.5%,对照组为67.5%,两组总有效率存在显著性差异（P〈0.05）。观察组在症状体征好转时间、体温恢复正常时间、痰液颜色改变时间、白细胞计数下降时间等方面均显著短于对照组（P〈0.05）。治疗后观察组细菌清除率为78.6%,显著高于对照组的52.0%（P〈0.05）。结论与单用头孢哌酮钠舒巴坦钠相比,莫西沙星联合头孢哌酮钠舒巴坦钠治疗老年重症肺炎具有高效、快速的优势,且没有明显增加不良反应的风险。
Objective To discuss the curative effects of moxifloxacin and cefoperazone/sulbactam sodium on elderly patients with severe pneumonia. Methods 80 elderly patients with severe pneumonia were selected and randomly divided into two groups.Control group received intravenous drip with 3.0 g cefoperazone/sulbactam sodium every 12 h. Based on the treatment above,observation group additionally received the intravenous drip with 0.4 g moxifloxacin. The course of treatment was 7-14 days. Results The total effective rate of the observation group was 87.5%, and that the control group was 67.5%. There was significant difference between the two groups（P 〈 0.05）. The improvement time of signs and symptoms, the recovery time of body temperature, the time of sputum color changes, and the time of leucopenia in the observation group were significantly shorter than those in the control group（P 〈 0.05）. After the treatment, the clearance rate of bacteria in the observation group was 78.6% which was significantly higher than that in the control group（52.0%）（P 〈 0.05）. Conclusion Compared with the single use of cefoperazone/sulbactam sodium, the combination of moxifloxacin and cefoperazone/sulbactam sodium has the advantages of effectiveness and quickness and has no obvious risk in the increase of adverse reactions.
出处
《西南国防医药》
CAS
2016年第3期252-254,共3页
Medical Journal of National Defending Forces in Southwest China
关键词
莫西沙星
头孢哌酮钠舒巴坦钠
老年
重症肺炎
疗效
moxifloxacin
cefoperazone/sulbactam sodium
elderly
severe pneumonia
curative effect
